These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27488745)

  • 21. [Recombinant human parathyroid hormone--new perspectives for anabolic therapy of osteoporosis].
    Miazgowski T; Stefański A
    Pol Arch Med Wewn; 2004 Oct; 112(4):1249-54. PubMed ID: 15773439
    [No Abstract]   [Full Text] [Related]  

  • 22. Tryptophan hydroxylase 1 (Tph-1)-targeted bone anabolic agents for osteoporosis.
    Fu HJ; Zhou YR; Bao BH; Jia MX; Zhao Y; Zhang L; Li JX; He HL; Zhou XM
    J Med Chem; 2014 Jun; 57(11):4692-709. PubMed ID: 24844139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacology of bone anabolic agents].
    Matsumoto T
    Nihon Rinsho; 2015 Oct; 73(10):1639-44. PubMed ID: 26529924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
    Lu N; Sun H; Yu J; Wang X; Liu D; Zhao L; Sun L; Zhao H; Tao B; Liu J
    PLoS One; 2015; 10(7):e0132744. PubMed ID: 26177280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future therapeutic targets in osteoporosis.
    Deal C
    Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?
    Liu J; Zhang H; Dong Y; Jin Y; Hu X; Cai K; Ma J; Wu G
    Med Hypotheses; 2014 Dec; 83(6):694-6. PubMed ID: 25459136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
    Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of coumarin-dihydropyridine hybrids as bone anabolic agents.
    Sashidhara KV; Kumar M; Khedgikar V; Kushwaha P; Modukuri RK; Kumar A; Gautam J; Singh D; Sridhar B; Trivedi R
    J Med Chem; 2013 Jan; 56(1):109-22. PubMed ID: 23214410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anabolic effects of PTH and the 'anabolic window'.
    Pazianas M
    Trends Endocrinol Metab; 2015 Mar; 26(3):111-3. PubMed ID: 25662368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The beneficial effect of icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats.
    Peng S; Zhang G; Zhang BT; Guo B; He Y; Bakker AJ; Pan X; Zhen W; Hung L; Qin L; Leung WN
    Bone; 2013 Jul; 55(1):230-40. PubMed ID: 23486180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three new players in energy regulation: preptin, adropin and irisin.
    Aydin S
    Peptides; 2014 Jun; 56():94-110. PubMed ID: 24721335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.
    Miao D; He B; Jiang Y; Kobayashi T; Sorocéanu MA; Zhao J; Su H; Tong X; Amizuka N; Gupta A; Genant HK; Kronenberg HM; Goltzman D; Karaplis AC
    J Clin Invest; 2005 Sep; 115(9):2402-11. PubMed ID: 16138191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic effects of high dietary calcium and exogenous parathyroid hormone in promoting osteoblastic bone formation in mice.
    Feng Y; Zhou M; Zhang Q; Liu H; Xu Y; Shu L; Zhang J; Miao D; Ren Y
    Br J Nutr; 2015 Mar; 113(6):909-22. PubMed ID: 25744000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
    Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
    Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of the percentage of increased spongy bone in experimental osteoporosis treated with synthetic anabolic agents].
    Carrozzo M; Pallante R; Lo Sasso F; D'Amore M
    Rev Rhum Mal Osteoartic; 1983 Jun; 50(7):501-5. PubMed ID: 6612200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
    Srivastava K; Tyagi AM; Khan K; Dixit M; Lahiri S; Kumar A; Changkija B; Khan MP; Nagar GK; Yadav DK; Maurya R; Singh SP; Jain GK; Wahajuddin ; Trivedi R; Chattopadhyay N; Singh D
    Phytomedicine; 2013 Apr; 20(6):470-80. PubMed ID: 23395215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteogenic growth peptide effects on primary human osteoblast cultures: potential relevance for the treatment of glucocorticoid-induced osteoporosis.
    Spreafico A; Frediani B; Capperucci C; Leonini A; Gambera D; Ferrata P; Rosini S; Di Stefano A; Galeazzi M; Marcolongo R
    J Cell Biochem; 2006 Jul; 98(4):1007-20. PubMed ID: 16795077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis.
    Kalgutkar AS; Griffith DA; Ryder T; Sun H; Miao Z; Bauman JN; Didiuk MT; Frederick KS; Zhao SX; Prakash C; Soglia JR; Bagley SW; Bechle BM; Kelley RM; Dirico K; Zawistoski M; Li J; Oliver R; Guzman-Perez A; Liu KK; Walker DP; Benbow JW; Morris J
    Chem Res Toxicol; 2010 Jun; 23(6):1115-26. PubMed ID: 20507089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of the bone anabolic agent by intravital imaging technique.].
    Morimoto A; Kikuta J; Furuya M; Ishii M
    Clin Calcium; 2018; 28(2):243-248. PubMed ID: 29371491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 3-amino-4-{(3S)-3-[(2-ethoxyethoxy)methyl]piperidin-1-yl}thieno[2,3-b]pyridine-2-carboxamide (DS96432529): A potent and orally active bone anabolic agent.
    Saito K; Shinozuka T; Nakao A; Kunikata T; Nakai D; Nagai Y; Naito S
    Bioorg Med Chem Lett; 2021 Dec; 54():128440. PubMed ID: 34742889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.